KNIGHT THERAPEUTICS INC (GUD.CA) Fundamental Analysis & Valuation

TSX:GUD • CA4990531069

Current stock price

7.45 CAD
+0.01 (+0.13%)
Last:

This GUD.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. GUD.CA Profitability Analysis

1.1 Basic Checks

  • GUD had negative earnings in the past year.
  • GUD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
  • In the past 5 years GUD always reported a positive cash flow from operatings.
GUD.CA Yearly Net Income VS EBIT VS OCF VS FCFGUD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.51%, GUD is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • With a decent Return On Equity value of -0.70%, GUD is doing good in the industry, outperforming 69.70% of the companies in the same industry.
  • GUD has a better Return On Invested Capital (0.38%) than 63.64% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GUD is significantly below the industry average of 8.22%.
Industry RankSector Rank
ROA -0.51%
ROE -0.7%
ROIC 0.38%
ROA(3y)-0.61%
ROA(5y)-0.62%
ROE(3y)-0.8%
ROE(5y)-0.83%
ROIC(3y)0.73%
ROIC(5y)N/A
GUD.CA Yearly ROA, ROE, ROICGUD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4

1.3 Margins

  • GUD has a better Operating Margin (1.02%) than 63.64% of its industry peers.
  • The Gross Margin of GUD (46.03%) is better than 63.64% of its industry peers.
  • GUD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.02%
PM (TTM) N/A
GM 46.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y2.42%
GUD.CA Yearly Profit, Operating, Gross MarginsGUD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GUD.CA Health Analysis

2.1 Basic Checks

  • GUD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, GUD has less shares outstanding
  • The number of shares outstanding for GUD has been reduced compared to 5 years ago.
  • GUD has a worse debt/assets ratio than last year.
GUD.CA Yearly Shares OutstandingGUD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
GUD.CA Yearly Total Debt VS Total AssetsGUD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • GUD has an Altman-Z score of 2.48. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of GUD (2.48) is better than 87.88% of its industry peers.
  • GUD has a debt to FCF ratio of 2.21. This is a good value and a sign of high solvency as GUD would need 2.21 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.21, GUD belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that GUD is not too dependend on debt financing.
  • GUD has a Debt to Equity ratio of 0.08. This is in the better half of the industry: GUD outperforms 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 2.21
Altman-Z 2.48
ROIC/WACC0.04
WACC8.64%
GUD.CA Yearly LT Debt VS Equity VS FCFGUD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • GUD has a Current Ratio of 2.39. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 2.39, GUD is doing good in the industry, outperforming 60.61% of the companies in the same industry.
  • GUD has a Quick Ratio of 1.57. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of GUD (1.57) is better than 69.70% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 1.57
GUD.CA Yearly Current Assets VS Current LiabilitesGUD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GUD.CA Growth Analysis

3.1 Past

  • GUD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -180.00%.
  • The Revenue has grown by 21.22% in the past year. This is a very strong growth!
  • Measured over the past years, GUD shows a quite strong growth in Revenue. The Revenue has been growing by 17.67% on average per year.
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y15.31%
Revenue growth 5Y17.67%
Sales Q2Q%37.42%

3.2 Future

  • Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 74.17% on average per year.
  • The Revenue is expected to grow by 7.67% on average over the next years.
EPS Next Y219.94%
EPS Next 2Y135.27%
EPS Next 3Y121.61%
EPS Next 5Y74.17%
Revenue Next Year8.04%
Revenue Next 2Y4.87%
Revenue Next 3Y8.29%
Revenue Next 5Y7.67%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GUD.CA Yearly Revenue VS EstimatesGUD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
GUD.CA Yearly EPS VS EstimatesGUD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

4

4. GUD.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GUD. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 155.29, which means the current valuation is very expensive for GUD.
  • GUD's Price/Forward Earnings is on the same level as the industry average.
  • GUD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.84.
Industry RankSector Rank
PE N/A
Fwd PE 155.29
GUD.CA Price Earnings VS Forward Price EarningsGUD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100

4.2 Price Multiples

  • 66.67% of the companies in the same industry are more expensive than GUD, based on the Enterprise Value to EBITDA ratio.
  • GUD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. GUD is cheaper than 63.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.71
EV/EBITDA 10.73
GUD.CA Per share dataGUD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • GUD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • GUD's earnings are expected to grow with 121.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y135.27%
EPS Next 3Y121.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GUD.CA Dividend Analysis

5.1 Amount

  • GUD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GUD.CA Fundamentals: All Metrics, Ratios and Statistics

KNIGHT THERAPEUTICS INC

TSX:GUD (4/2/2026, 7:00:00 PM)

7.45

+0.01 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-06
Inst Owners16.05%
Inst Owner ChangeN/A
Ins Owners1.89%
Ins Owner ChangeN/A
Market Cap730.32M
Revenue(TTM)450.09M
Net Income(TTM)-5.37M
Analysts78
Price Target8.36 (12.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)298.02%
Min EPS beat(2)-692.08%
Max EPS beat(2)1288.12%
EPS beat(4)2
Avg EPS beat(4)36.72%
Min EPS beat(4)-815.07%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)-48.06%
EPS beat(12)6
Avg EPS beat(12)-79.01%
EPS beat(16)8
Avg EPS beat(16)-61.66%
Revenue beat(2)2
Avg Revenue beat(2)12.4%
Min Revenue beat(2)12.31%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)9.18%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)8
Avg Revenue beat(8)7.71%
Revenue beat(12)11
Avg Revenue beat(12)7.12%
Revenue beat(16)15
Avg Revenue beat(16)9.9%
PT rev (1m)3.26%
PT rev (3m)4.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)13.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 155.29
P/S 1.62
P/FCF 20.71
P/OCF 10.59
P/B 0.95
P/tB 2.45
EV/EBITDA 10.73
EPS(TTM)-0.04
EYN/A
EPS(NY)0.05
Fwd EY0.64%
FCF(TTM)0.36
FCFY4.83%
OCF(TTM)0.7
OCFY9.44%
SpS4.59
BVpS7.83
TBVpS3.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.51%
ROE -0.7%
ROCE 0.52%
ROIC 0.38%
ROICexc 0.43%
ROICexgc 1.12%
OM 1.02%
PM (TTM) N/A
GM 46.03%
FCFM 7.83%
ROA(3y)-0.61%
ROA(5y)-0.62%
ROE(3y)-0.8%
ROE(5y)-0.83%
ROIC(3y)0.73%
ROIC(5y)N/A
ROICexc(3y)0.89%
ROICexc(5y)N/A
ROICexgc(3y)2.02%
ROICexgc(5y)N/A
ROCE(3y)1.02%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y2.42%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 2.21
Debt/EBITDA 0.94
Cap/Depr 59.56%
Cap/Sales 7.49%
Interest Coverage 0.61
Cash Conversion 112.72%
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 1.57
Altman-Z 2.48
F-Score4
WACC8.64%
ROIC/WACC0.04
Cap/Depr(3y)46.19%
Cap/Depr(5y)129.54%
Cap/Sales(3y)6.33%
Cap/Sales(5y)23.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y219.94%
EPS Next 2Y135.27%
EPS Next 3Y121.61%
EPS Next 5Y74.17%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y15.31%
Revenue growth 5Y17.67%
Sales Q2Q%37.42%
Revenue Next Year8.04%
Revenue Next 2Y4.87%
Revenue Next 3Y8.29%
Revenue Next 5Y7.67%
EBIT growth 1Y352.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year360.79%
EBIT Next 3Y83.95%
EBIT Next 5Y51.89%
FCF growth 1Y633.42%
FCF growth 3Y22.5%
FCF growth 5YN/A
OCF growth 1Y90.07%
OCF growth 3Y15.29%
OCF growth 5YN/A

KNIGHT THERAPEUTICS INC / GUD.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 5 / 10 to GUD.CA.


What is the valuation status for GUD stock?

ChartMill assigns a valuation rating of 4 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Fairly Valued.


How profitable is KNIGHT THERAPEUTICS INC (GUD.CA) stock?

KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for GUD stock?

The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to grow by 219.94% in the next year.